Cargando…

UNITE4TB: a new consortium for clinical drug and regimen development for TB

Detalles Bibliográficos
Autores principales:	Boeree, M. J., Lange, C., Thwaites, G., Paton, N., de Vrueh, R., Barros, D., Hoelscher, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Union Against Tuberculosis and Lung Disease 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544922/ https://www.ncbi.nlm.nih.gov/pubmed/34686229 http://dx.doi.org/10.5588/ijtld.21.0515

Ejemplares similares

The Cost-Effectiveness of the BEAT-TB Regimen for Pre-Extensively Drug-Resistant TB
por: Muniyandi, Malaisamy, et al.
Publicado: (2023)

Is intermittent short-course anti-TB regimen as efficient and safe as daily anti-TB regimen for treating childhood TB?
por: Bhaumik, Soumyadeep
Publicado: (2015)

Can Pan-TB shorter regimens be a promising hope for ending TB in India by 2025 in ongoing COVID-19 era?
por: Prasad, Rajendra, et al.
Publicado: (2022)

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic
por: Tiberi, Simon, et al.
Publicado: (2021)

New treatments for Drug Resistant TB: Past imperfect, future bright
por: Udwadia, Zarir F., et al.
Publicado: (2023)

Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy
por: Sweeney, Sedona, et al.
Publicado: (2020)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

TB Anywhere is TB Everywhere
por: Wortham, Jonathan M.
Publicado: (2018)

World TB Day 2018: The Challenge of Drug Resistant Tuberculosis
por: Gupta-Wright, Ankur, et al.
Publicado: (2018)

Investigating the response to COVID-19 and understanding severe TB cases: The 2022 Pulmonology TB series
por: Migliori, G.B., et al.
Publicado: (2022)

Shorter TB treatment regimens should be safer as well
por: Rucsineanu, O., et al.
Publicado: (2023)

Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients
por: Mtabho, Charles M, et al.
Publicado: (2019)

Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now
por: Chowdhury, Kona, et al.
Publicado: (2023)

Implementing the 4R and 9H regimens for TB preventive treatment in Indonesia
por: Apriani, L., et al.
Publicado: (2022)

Drug Susceptibility of Mycobacterium tuberculosis Beijing Genotype and Association with MDR TB
por: de Steenwinkel, Jurriaan E.M., et al.
Publicado: (2012)

Society and its leading role in the history of TB in Brazil: Celebrating 18 years of STOP-TB Brazil
por: Lindner, Liandro, et al.
Publicado: (2023)

Tuberculosis Diagnostics in the New Millennium: Role in TB Identification and Control
por: Chakravorty, Soumitesh, et al.
Publicado: (2012)

TB or not TB! That’s the question
por: Nugud, Ahmed, et al.
Publicado: (2019)

Editorial: TB on the rise: but researchers are not sleeping
por: Tumwine, James K
Publicado: (2021)

TB/Covid-19: An Underestimated Risk?
por: Sotgiu, Giovanni, et al.
Publicado: (2022)

Heightened Vulnerability to MDR-TB Epidemics after Controlling Drug-Susceptible TB
por: Bishai, Jason D., et al.
Publicado: (2010)

Confronting TB/HIV in the era of increasing anti-TB drug resistance
por: Chakaya, Jeremiah, et al.
Publicado: (2008)

Effect of TB Treatment on Neutrophil-Derived Soluble Inflammatory Mediators in TB Patients with and without HIV Coinfection
por: Sitoe, Nádia, et al.
Publicado: (2023)

Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
por: Singh, Pravin K., et al.
Publicado: (2019)

Assessment of Effective Anti-TB Regimens and Adverse Outcomes Related Risk Factors in the Elderly and Senile-Aged TB Patients
por: Guo, Jing, et al.
Publicado: (2023)

Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance
por: Lienhardt, Christian, et al.
Publicado: (2019)

Atripla(R)/anti-TB combination in TB/HIV patients. Drug in focus
por: Semvua, Hadija H, et al.
Publicado: (2011)

Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen
por: Mantefardo, Bahru, et al.
Publicado: (2021)

Impact of COVID-19 and tobacco on TB control
por: Chopra, K.K., et al.
Publicado: (2021)

Pharmacy engagement in TB prevention and care: not if, but how?
por: Miller, Rosalind, et al.
Publicado: (2023)

TB vaccine development and the End TB Strategy: importance and current status
por: Fletcher, Helen A., et al.
Publicado: (2016)

Performance of spirometry assessment at TB diagnosis
por: Rachow, A., et al.
Publicado: (2023)

Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial
por: Weng, Taoping, et al.
Publicado: (2021)

Enhancing TB Case Detection: Experience in Offering Upfront Xpert MTB/RIF Testing to Pediatric Presumptive TB and DR TB Cases for Early Rapid Diagnosis of Drug Sensitive and Drug Resistant TB
por: Raizada, Neeraj, et al.
Publicado: (2014)

Uniting to end the TB epidemic: advances in disease control from prevention to better diagnosis and treatment
por: Abubakar, Ibrahim, et al.
Publicado: (2016)

Development of chronic lung impairment in Mozambican TB patients and associated risks
por: Khosa, Celso, et al.
Publicado: (2020)

The TB vaccine development pathway – An innovative approach to accelerating global TB vaccine development
por: Roordink, Danielle, et al.
Publicado: (2021)

World TB Day 2022: Revamping and Reshaping Global TB Control Programs by Advancing Lessons learnt from the COVID-19 pandemic
por: Petersen, Eskild, et al.
Publicado: (2022)

Striking the Right Balance Determines TB or Not TB
por: BoseDasgupta, Somdeb, et al.
Publicado: (2014)

Clinical standards for drug-susceptible pulmonary TB
por: Akkerman, O. W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qkncmmlqb441d3tstd1sdj19n5